7-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚 | 200714-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚
• 中文别名: 7-氟-3-(1,2,3,6-四氢-4-吡啶基)-1H-吲哚
• 英文名称: 7-Fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
• 英文别名: 7-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole；4-(7-Fluoroindol-3-yl)-1,2,5,6-tetrahydropyridine
• CAS: 200714-22-3
• 化学式: C₁₃H₁₃FN₂
• 分子量: 216.258
• InChiKey: LGCVGUGCTQBGJA-UHFFFAOYSA-N

物化性质

• 沸点：
  403.6±45.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  7-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚 、 3,3-dimethyl-1-(2-methanesulfonyloxy-1-ethyl)-1,3-dihydro-2H-indol-2-one 生成 3,3-Dimethyl-1-{2-[4-(7-fluoroindol-3-yl)-1,2,5,6-tetrahydro-1-pyridyl]-1-ethyl}-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  US6166040

  摘要：

  公开号：
• 作为产物：
  描述：

  7-氟吲哚 、 4-piperidone monohydrochloride monohydrate 生成 7-氟-3-(1,2,3,6-四氢吡啶-4-基)-1H-吲哚
  参考文献：
  名称：

  Inhibition of serotonin reuptake

  摘要：

  本发明提供了一种用于抑制哺乳动物中5-羟色胺再摄取的化合物和方法。

  公开号：

  US05846982A1

文献信息

• Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP0897921A1

  公开（公告）日：1999-02-24

  Compounds having the formula: in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R1 and R2 are each hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, C1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C1-4 alkyl, or R3 and R4 together form an alkylene link of formula -(CH2)3- or -(CH2)4-, or R4 and R5 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, R6 is C1-4 alkyl, C1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof, are binding to the 5-HT serotonin receptor and are useful in the treatment of CNS disorders.

  具有以下化学式的化合物： 其中n为1或2，m为1或2， p为1至6，q为0或1至3， R1和R2分别为氢或C1-4烷基， R3、R4和R5分别为氢、C1-4烷基、可选择取代的苯基或可选择取代的苯基-C1-4烷基，或者R3和R4一起形成化学式-(CH2)3-或-(CH2)4-的烷基链，或者R4和R5与它们连接的碳原子一起形成C3-6环烷基团， R6为C1-4烷基、C1-4烷氧基、羧基、羟基、氰基、卤素、三氟甲基、硝基或氨基， 虚线表示可选的双键，和 氟原子连接在6位或7位； 以及它们的盐和酯，与5-HT血清素受体结合，并在中枢神经系统疾病的治疗中有用。
• Pharmaceutical compounds
  申请人：——

  公开号：US20040122001A1

  公开（公告）日：2004-06-24

  This invention relates to compounds of formula (I) where R 1 to R 12 , —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals. 1

  这项发明涉及到式(I)的化合物，其中R1至R12，—W—V—，—X—Y—，m和n的值如权利要求1中定义的，它们的制备和用作药物。
• ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE
  申请人：Wyeth

  公开号：US20030134871A1

  公开（公告）日：2003-07-17

  Compounds of the formula: 1 useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.

  这种化合物的公式：1可用于治疗抑郁症和其他疾病，如强迫症、恐慌发作、广泛性焦虑障碍、社交焦虑障碍、性功能障碍、进食障碍、肥胖症、由乙醇或可卡因滥用引起的成瘾障碍及相关疾病。
• Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
  申请人：Wyeth

  公开号：US20020183351A1

  公开（公告）日：2002-12-05

  Compounds of the formula: 1 are useful for the treatment of depression and other diseases such as obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse and related illnesses.

  这种化合物的公式：1对治疗抑郁症和其他疾病非常有用，如强迫症、恐慌发作、广泛性焦虑障碍、社交焦虑障碍、性功能障碍、饮食障碍、肥胖、由乙醇或可卡因滥用引起的成瘾障碍以及相关疾病。
• 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake
  申请人：ELI LILLY AND COMPANY

  公开号：EP0812826A1

  公开（公告）日：1997-12-17

  The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1 is H, halo, formyl, C1-C4 alkyl, C1-C4 alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2 is H or halo; R3 is H, C1-C4 alkyl, (C1-C4 alkylene)-aryl, or -CH2-Y-NR7R8; R4 is H, C1-C4 alkyl, C1-C5 acyl, or phenylsulfonyl; R5 is H or OH; R6 is H or methyl; Y is -CH2- or -C(O)-; R7 is pyridinyl; and R8 is H or -C(O)-(C3-C6 cycloalkyl); and pharmaceutically acceptable salts thereof.

  化合物的药用途：其中Z是formulaA-B结构，-C=CH-或-C(R5)-CH2-；X是S或NR4；R1是H、卤素、甲酰基、C1-C4烷基、C1-C4烷氧基、噻吩甲氧基、4,5-二氢噻唑-2-基、氰基、硝基、羧酰胺基、三氟甲基或羟基；R2是H或卤素；R3是H、C1-C4烷基、(C1-C4烷基)-芳基，或-CH2-Y-NR7R8；R4是H、C1-C4烷基、C1-C5酰基，或苯基磺酰基；R5是H或OH；R6是H或甲基；Y是-CH2-或-C(O)-；R7是吡啶基；R8是H或-C(O)-(C3-C6环烷基)；以及其药用上可接受的盐。